Genzyme and Bone Care International Announce Completion of Hart-Scott-Rodino Review
17-Jun-2005
As announced on May 4, 2005, Genzyme and Bone Care have signed a definitive merger agreement under which Genzyme will acquire Bone Care in an all cash transaction valued at $33.00 per fully diluted share. The transaction remains subject to approval by Bone Care's shareholders at a meeting on June 30, and other customary closing conditions.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.